Here's some of what is coming soon to NeurologyLive® this week.
|Articles|December 30, 2019
NeurologyLive Year in Review: Top Peer Exchange Segments
Author(s)Matt Hoffman
Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.
Advertisement
NeurologyLive seeks to bring expert-driven insight to the forefront of its coverage, and we did so in 2019 by gathering experts in a number of subspecialties together to lead discussions on pressing topics within their respective fields in our
These multi-part conversations cover topics ranging from diagnosis and making treatment decisions, to the use of genetic testing and the understanding of the biologic basis for diseases. These discussions among peers are a pillar of our offerings to clinicians and health care professionals in neurology to help you improve patient care. We've assembled some of the best of those conversations from this past year below.
Click the links below to watch some of our most popular Peer Exchange segments of 2019:
Evolving Knowledge of Epilepsy Incidence and Etiology —
Diagnosing MS in the Modern Era —
CGRP Inhibitors: Transformative Therapy for Migraine —
Biology of Migraine —
Diagnostic Tests to Confirm hATTR Amyloidosis —
Functional Changes in the Brain During Migraine —
Early Identification and Diagnosis of MS —
Response to CGRP Inhibitors: Refractory Migraine & Drug Overuse —
Considerations for Using Oral Cladribine in MS —
Defining hATTR Amyloidosis —
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA
2
Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show
3
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
4
Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis
5